MREO

Mereo BioPharma Group (MREO)

About Mereo BioPharma Group (MREO)

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Details

Daily high

$2.13

Daily low

$1.88

Price at open

$2.10

52 Week High

$3.88

52 Week Low

$1.47

Market cap

334.1M

Dividend yield

0.00%

Volume

3.0M

Avg. volume

2.3M

P/E ratio

-7.97

Mereo BioPharma Group News